A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors
Latest Information Update: 14 Jul 2023
At a glance
- Drugs VT-1021 (Primary)
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Glioblastoma; Male breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Vigeo Therapeutics
- 13 Jul 2023 According to a Vigeo Therapeutics media release, the company announced that a complete response patient (CR) in Glioblastoma (GBM) cohort from first in human study VT1021-01 (NCT03364400) has now completed 3 full years of dosing with VT1021.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2023 New clinical and immune profiling data from phase 1/2 expansion study presented in the Vigeo Therapeutics Media Release.